Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 264

1.

Dynamic change of fatigue of pemetrexed maintenance treatment in the JMEN trial.

Zhang L, Belani CP, Zhang PH, Wang X, Yang L, Orlando M, Wu YL.

Lung Cancer. 2018 Jan;115:121-126. doi: 10.1016/j.lungcan.2017.11.026. Epub 2017 Nov 28.

PMID:
29290253
2.

Rapid magnetic isolation of extracellular vesicles via lipid-based nanoprobes.

Wan Y, Cheng G, Liu X, Hao SJ, Nisic M, Zhu CD, Xia YQ, Li WQ, Wang ZG, Zhang WL, Rice SJ, Sebastian A, Albert I, Belani CP, Zheng SY.

Nat Biomed Eng. 2017;1. pii: 0058. doi: 10.1038/s41551-017-0058. Epub 2017 Apr 10.

3.

Posttraumatic Symptoms, Quality of Life, and Survival among Lung Cancer Patients.

Dougall AL, Swanson J, Kyutoku Y, Belani CP, Baum A.

J Appl Biobehav Res. 2017 Sep;22(3). pii: e12065. doi: 10.1111/jabr.12065. Epub 2017 Apr 18.

PMID:
28966544
4.

Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature.

Pillai RN, Behera M, Owonikoko TK, Kamphorst AO, Pakkala S, Belani CP, Khuri FR, Ahmed R, Ramalingam SS.

Cancer. 2018 Jan 15;124(2):271-277. doi: 10.1002/cncr.31043. Epub 2017 Sep 28.

PMID:
28960263
5.

Phase I study of veliparib in combination with gemcitabine.

Stoller R, Schmitz JC, Ding F, Puhalla S, Belani CP, Appleman L, Lin Y, Jiang Y, Almokadem S, Petro D, Holleran J, Kiesel BF, Ken Czambel R, Carneiro BA, Kontopodis E, Hershberger PA, Rachid M, Chen A, Chu E, Beumer JH.

Cancer Chemother Pharmacol. 2017 Sep;80(3):631-643. doi: 10.1007/s00280-017-3409-3. Epub 2017 Aug 2.

6.

National Cancer Database Analysis of Proton Versus Photon Radiation Therapy in Non-Small Cell Lung Cancer.

Higgins KA, O'Connell K, Liu Y, Gillespie TW, McDonald MW, Pillai RN, Patel KR, Patel PR, Robinson CG, Simone CB 2nd, Owonikoko TK, Belani CP, Khuri FR, Curran WJ, Ramalingam SS, Behera M.

Int J Radiat Oncol Biol Phys. 2017 Jan 1;97(1):128-137. doi: 10.1016/j.ijrobp.2016.10.001. Epub 2016 Oct 11.

7.

Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer: A Systematic Review.

Steuer CE, Behera M, Ernani V, Higgins KA, Saba NF, Shin DM, Pakkala S, Pillai RN, Owonikoko TK, Curran WJ, Belani CP, Khuri FR, Ramalingam SS.

JAMA Oncol. 2017 Aug 1;3(8):1120-1129. doi: 10.1001/jamaoncol.2016.4280. Review.

PMID:
27978552
8.

A randomized trial of TLR-2 agonist CADI-05 targeting desmocollin-3 for advanced non-small-cell lung cancer.

Belani CP, Chakraborty BC, Modi RI, Khamar BM.

Ann Oncol. 2017 Feb 1;28(2):298-304. doi: 10.1093/annonc/mdw608.

PMID:
27831503
9.

Pulmonary Rehabilitation in Lung Cancer.

Wang H, Liu X, Rice SJ, Belani CP.

PM R. 2016 Oct;8(10):990-996. doi: 10.1016/j.pmrj.2016.03.010. Epub 2016 Apr 6. Review.

PMID:
27060645
10.

Docetaxel Combined With Bavituximab in Previously Treated, Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Gerber DE, Spigel DR, Giorgadze D, Shtivelband M, Ponomarova OV, Shan JS, Menander KB, Belani CP.

Clin Lung Cancer. 2016 May;17(3):169-76. doi: 10.1016/j.cllc.2016.02.003. Epub 2016 Feb 19.

11.

Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer.

Zheng H, Liu X, Zhang J, Rice SJ, Wagman M, Kong Y, Zhu L, Zhu J, Joshi M, Belani CP.

Oncotarget. 2016 Aug 30;7(35):56233-56240. doi: 10.18632/oncotarget.9316.

12.

Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508).

Belani CP, Dahlberg SE, Rudin CM, Fleisher M, Chen HX, Takebe N, Velasco MR Jr, Tester WJ, Sturtz K, Hann CL, Shanks JC, Monga M, Ramalingam SS, Schiller JH.

Cancer. 2016 Aug 1;122(15):2371-8. doi: 10.1002/cncr.30062. Epub 2016 May 10.

13.

A patient with complex multiple genomic ALK alterations.

Liu X, Rice SJ, Jamis-Dow CA, Abendroth C, Ali S, Almokadem S, Belani CP.

Thorax. 2016 Apr;71(4):383-5. doi: 10.1136/thoraxjnl-2015-207950. Epub 2016 Feb 2. No abstract available.

PMID:
26839360
14.

Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005.

Behera M, Ragin C, Kim S, Pillai RN, Chen Z, Steuer CE, Saba NF, Belani CP, Khuri FR, Ramalingam SS, Owonikoko TK.

Cancer. 2016 Jan 1;122(1):50-60. doi: 10.1002/cncr.29674. Epub 2015 Oct 6.

15.

Bevacizumab in Combination with Taxane versus Non-Taxane Containing Regimens for Advanced/Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Systematic Review.

Behera M, Pillai RN, Owonikoko TK, Kim S, Steuer C, Chen Z, Saba NF, Belani CP, Khuri FR, Ramalingam SS.

J Thorac Oncol. 2015 Aug;10(8):1142-7. doi: 10.1097/JTO.0000000000000572. Review.

16.

Clinical Approaches to Immunotherapy in Non-Small Cell Lung Cancer: Current and Future Perspectives.

Rice SJ, Miller B, Wagman M, Jamorabo DS, Liu X, Belani CP.

Curr Mol Pharmacol. 2016;9(3):183-195. Review.

PMID:
26177648
17.

Editorial (Thematic Issue: Clinical Advances in Immuno-oncology - Progress Towards Selective Cure).

Liu X, Belani CP.

Curr Mol Pharmacol. 2016;9(3):182. No abstract available.

PMID:
26177639
18.

Proteomic profiling of human plasma identifies apolipoprotein E as being associated with smoking and a marker for squamous metaplasia of the lung.

Rice SJ, Liu X, Miller B, Joshi M, Zhu J, Caruso C, Gilbert C, Toth J, Reed M, Rassaei N, Das A, Barochia A, El-Bayoumy K, Belani CP.

Proteomics. 2015 Sep;15(18):3267-77. doi: 10.1002/pmic.201500029. Epub 2015 Jul 3.

PMID:
26058877
19.

A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511).

Owonikoko TK, Dahlberg SE, Khan SA, Gerber DE, Dowell J, Moss RA, Belani CP, Hann CL, Aggarwal C, Ramalingam SS.

Lung Cancer. 2015 Jul;89(1):66-70. doi: 10.1016/j.lungcan.2015.04.015. Epub 2015 May 8.

20.

Afatinib for the treatment of metastatic non-small cell lung cancer.

Joshi M, Rizvi SM, Belani CP.

Cancer Manag Res. 2015 Feb 19;7:75-82. doi: 10.2147/CMAR.S51808. eCollection 2015. Review.

21.

Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.

Joshi M, Rice SJ, Liu X, Miller B, Belani CP.

PLoS One. 2015 Feb 23;10(2):e0118210. doi: 10.1371/journal.pone.0118210. eCollection 2015.

22.

Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer.

Ramalingam SS, Shtivelband M, Soo RA, Barrios CH, Makhson A, Segalla JG, Pittman KB, Kolman P, Pereira JR, Srkalovic G, Belani CP, Axelrod R, Owonikoko TK, Qin Q, Qian J, McKeegan EM, Devanarayan V, McKee MD, Ricker JL, Carlson DM, Gorbunova VA.

J Clin Oncol. 2015 Feb 10;33(5):433-41. doi: 10.1200/JCO.2014.55.7173. Epub 2015 Jan 5.

23.

Complex chronic conditions in Rhode Island's pediatric populace: implications for palliative and hospice services, 2000-2012.

Jamorabo DS, Belani CP, Martin EW.

J Palliat Med. 2015 Apr;18(4):350-7. doi: 10.1089/jpm.2014.0226. Epub 2014 Dec 18.

PMID:
25522161
24.

A phase i study of DMS612, a novel bifunctional alkylating agent.

Appleman LJ, Balasubramaniam S, Parise RA, Bryla C, Redon CE, Nakamura AJ, Bonner WM, Wright JJ, Piekarz R, Kohler DR, Jiang Y, Belani CP, Eiseman J, Chu E, Beumer JH, Bates SE.

Clin Cancer Res. 2015 Feb 15;21(4):721-9. doi: 10.1158/1078-0432.CCR-14-1333. Epub 2014 Dec 2.

25.

Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer.

Jiang Y, Mackley HB, Kimchi ET, Zhu J, Gusani N, Kaifi J, Staveley-O'Carroll KF, Belani CP.

Cancer Chemother Pharmacol. 2014 Jul;74(1):205-10. doi: 10.1007/s00280-014-2488-7. Epub 2014 Jun 8.

PMID:
24908435
26.

Targeted immunotherapy for non-small cell lung cancer.

Vasekar M, Liu X, Zheng H, Belani CP.

World J Clin Oncol. 2014 May 10;5(2):39-47. doi: 10.5306/wjco.v5.i2.39. Review.

27.

Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer.

Belani CP, Yamamoto N, Bondarenko IM, Poltoratskiy A, Novello S, Tang J, Bycott P, Niethammer AG, Ingrosso A, Kim S, Scagliotti GV.

BMC Cancer. 2014 Apr 25;14:290. doi: 10.1186/1471-2407-14-290.

28.

Would screening for lung cancer benefit 75- to 84-year-old residents of the United States?

Varlotto JM, Decamp MM, Flickinger JC, Lake J, Recht A, Belani CP, Reed MF, Toth JW, Mackley HB, Sciamanna CN, Lipton A, Ali SM, Mahraj RP, Gilbert CR, Yao N.

Front Oncol. 2014 Mar 7;4:37. doi: 10.3389/fonc.2014.00037. eCollection 2014.

29.

Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer.

Ji C, Zhang L, Cheng Y, Patel R, Wu H, Zhang Y, Wang M, Ji S, Belani CP, Yang JM, Ren X.

Cancer Biol Ther. 2014 May;15(5):570-7. doi: 10.4161/cbt.28162. Epub 2014 Feb 20.

30.

Taxanes, past, present, and future impact on non-small cell lung cancer.

Joshi M, Liu X, Belani CP.

Anticancer Drugs. 2014 May;25(5):571-83. doi: 10.1097/CAD.0000000000000080. Review.

PMID:
24463482
31.

Endobronchial valve placement for spontaneous pneumothorax from stage IIIA non-small cell lung cancer facilitates neoadjuvant therapy.

Gilbert CR, Toth JW, Kaifi JT, Belani CP, Varlotto J, Reed MF.

Ann Thorac Surg. 2013 Dec;96(6):2225-7. doi: 10.1016/j.athoracsur.2013.04.119.

PMID:
24296192
32.

Flexible micro spring array device for high-throughput enrichment of viable circulating tumor cells.

Harouaka RA, Zhou MD, Yeh YT, Khan WJ, Das A, Liu X, Christ CC, Dicker DT, Baney TS, Kaifi JT, Belani CP, Truica CI, El-Deiry WS, Allerton JP, Zheng SY.

Clin Chem. 2014 Feb;60(2):323-33. doi: 10.1373/clinchem.2013.206805. Epub 2013 Oct 16.

33.

A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer.

Ramalingam SS, Kotsakis A, Tarhini AA, Heron DE, Smith R, Friedland D, Petro DP, Raez LE, Brahmer JR, Greenberger JS, Dacic S, Hershberger P, Landreneau RJ, Luketich JD, Belani CP, Argiris A.

Lung Cancer. 2013 Sep;81(3):416-21. doi: 10.1016/j.lungcan.2013.06.002. Epub 2013 Jul 10.

PMID:
23849982
34.

Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer.

Belani CP, Nemunaitis JJ, Chachoua A, Eisenberg PD, Raez LE, Cuevas JD, Mather CB, Benner RJ, Meech SJ.

Cancer Biol Ther. 2013 Jul;14(7):557-63. doi: 10.4161/cbt.24598. Epub 2013 May 10.

35.

Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data.

Mauguen A, Pignon JP, Burdett S, Domerg C, Fisher D, Paulus R, Mandrekar SJ, Belani CP, Shepherd FA, Eisen T, Pang H, Collette L, Sause WT, Dahlberg SE, Crawford J, O'Brien M, Schild SE, Parmar M, Tierney JF, Le Pechoux C, Michiels S; Surrogate Lung Project Collaborative Group.

Lancet Oncol. 2013 Jun;14(7):619-26. doi: 10.1016/S1470-2045(13)70158-X. Epub 2013 May 14.

36.

Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.

Shibata SI, Chung V, Synold TW, Longmate JA, Suttle AB, Ottesen LH, Lenz HJ, Kummar S, Harvey RD, Hamilton AL, O'Neil BH, Sarantopoulos J, LoRusso P, Rudek MA, Dowlati A, Mulkerin DL, Belani CP, Gandhi L, Lau SC, Ivy SP, Newman EM.

Clin Cancer Res. 2013 Jul 1;19(13):3631-9. doi: 10.1158/1078-0432.CCR-12-3214. Epub 2013 May 7.

37.

Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN).

Obasaju C, Bowman L, Wang P, Shen W, Winfree KB, Smyth EN, Boye ME, John W, Brodowicz T, Belani CP.

Ann Oncol. 2013 Jun;24(6):1534-42. doi: 10.1093/annonc/mdt123. Epub 2013 Apr 4.

38.

A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.

Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic V, Horn L, Paschold E, Salgia R, West H, Sequist LV, Bonomi P, Brahmer J, Chen LC, Sandler A, Belani CP, Webb T, Harper H, Huberman M, Ramalingam S, Wong KK, Teofilovici F, Guo W, Shapiro GI.

Clin Cancer Res. 2013 Jun 1;19(11):3068-77. doi: 10.1158/1078-0432.CCR-12-3381. Epub 2013 Apr 3.

39.

A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies.

Chow LQ, Jonker DI, Dy GK, Nicholas G, Fortin C, Patricia D, Adjei AA, Belani CP, Gupta A, Park JS, Zhang S, Sbar EI, Laurie SA.

Cancer Chemother Pharmacol. 2013 May;71(5):1273-85. doi: 10.1007/s00280-013-2126-9. Epub 2013 Mar 7.

PMID:
23468081
40.

Small-cell lung cancer: an update on targeted therapies.

Joshi M, Ayoola A, Belani CP.

Adv Exp Med Biol. 2013;779:385-404. doi: 10.1007/978-1-4614-6176-0_18. Review.

PMID:
23288650
41.

Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients.

Wu H, Ramanathan RK, Zamboni BA, Strychor S, Ramalingam S, Edwards RP, Friedland DM, Stoller RG, Belani CP, Maruca LJ, Bang YJ, Zamboni WC.

Int J Nanomedicine. 2012;7:5555-64. doi: 10.2147/IJN.S35751. Epub 2012 Oct 19.

42.

Phase Ib safety and pharmacokinetic study of volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer.

Besse B, Tsao LC, Chao DT, Fang Y, Soria JC, Almokadem S, Belani CP.

Ann Oncol. 2013 Jan;24(1):90-6. doi: 10.1093/annonc/mds281. Epub 2012 Aug 16.

PMID:
22904239
43.

Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building.

Sherer EA, Sale ME, Pollock BG, Belani CP, Egorin MJ, Ivy PS, Lieberman JA, Manuck SB, Marder SR, Muldoon MF, Scher HI, Solit DB, Bies RR.

J Pharmacokinet Pharmacodyn. 2012 Aug;39(4):393-414. doi: 10.1007/s10928-012-9258-0. Epub 2012 Jul 6.

44.

Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis.

Mauguen A, Le Péchoux C, Saunders MI, Schild SE, Turrisi AT, Baumann M, Sause WT, Ball D, Belani CP, Bonner JA, Zajusz A, Dahlberg SE, Nankivell M, Mandrekar SJ, Paulus R, Behrendt K, Koch R, Bishop JF, Dische S, Arriagada R, De Ruysscher D, Pignon JP.

J Clin Oncol. 2012 Aug 1;30(22):2788-97. doi: 10.1200/JCO.2012.41.6677. Epub 2012 Jul 2.

45.

Surgical management of early-stage non-small cell lung carcinoma and the present and future roles of adjuvant therapy: a review for the radiation oncologist.

Medford-Davis L, Decamp M, Recht A, Flickinger J, Belani CP, Varlotto J.

Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1048-57. doi: 10.1016/j.ijrobp.2012.03.018. Epub 2012 May 23. Review.

PMID:
22632771
46.

Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update.

Ayoola A, Barochia A, Belani K, Belani CP.

Cancer Invest. 2012 Jun;30(5):433-46. doi: 10.3109/07357907.2012.666691. Review.

PMID:
22571344
47.

Single agent maintenance therapy for advanced stage non-small cell lung cancer: a meta-analysis.

Behera M, Owonikoko TK, Chen Z, Kono SA, Khuri FR, Belani CP, Ramalingam SS.

Lung Cancer. 2012 Aug;77(2):331-8. doi: 10.1016/j.lungcan.2012.03.019. Epub 2012 Apr 28.

48.

Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors.

Aregbe AO, Sherer EA, Egorin MJ, Scher HI, Solit DB, Ramanathan RK, Ramalingam S, Belani CP, Ivy PS, Bies RR.

Cancer Chemother Pharmacol. 2012 Jul;70(1):201-5. doi: 10.1007/s00280-012-1859-1. Epub 2012 Mar 27.

49.

Maintenance therapy for advanced non-small-cell lung cancer: switch versus continuation.

Joshi M, Jiang Y, Belani CP.

Expert Opin Pharmacother. 2012 Apr;13(5):685-97. doi: 10.1517/14656566.2012.668530. Epub 2012 Mar 10. Review.

PMID:
22404744
50.

Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study.

Belani CP, Brodowicz T, Ciuleanu TE, Krzakowski M, Yang SH, Franke F, Cucevic B, Madhavan J, Santoro A, Ramlau R, Liepa AM, Visseren-Grul C, Peterson P, John WJ, Zielinski CC.

Lancet Oncol. 2012 Mar;13(3):292-9. doi: 10.1016/S1470-2045(11)70339-4. Epub 2012 Feb 14.

PMID:
22336221

Supplemental Content

Loading ...
Support Center